Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30075127.
- Also identified by DOI 10.1016/j.stem.2018.07.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CAR-T therapy has shown great success treating blood cancers, but drawbacks include high manufacturing costs and potentially fatal toxicities such as cytokine release syndrome. In this issue of Cell Stem Cell, Li et al. (2018) describe how engineered iPSC-derived NK cells armed with NK-tailored CAR constructs (CAR-iPSC-NK cells) provide better options for anti-cancer immunotherapy.
Medical subject headings
- Immunotherapy, Adoptive
- Neoplasms